GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » K Pharma Inc (TSE:4896) » Definitions » Long-Term Debt

K Pharma (TSE:4896) Long-Term Debt : 円0 Mil (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is K Pharma Long-Term Debt?

K Pharma's Long-Term Debt for the quarter that ended in Mar. 2024 was 円0 Mil.


K Pharma Long-Term Debt Historical Data

The historical data trend for K Pharma's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

K Pharma Long-Term Debt Chart

K Pharma Annual Data
Trend Dec21 Dec22 Dec23
Long-Term Debt
- - -

K Pharma Quarterly Data
Dec21 Dec22 Jun23 Sep23 Dec23 Mar24
Long-Term Debt Get a 7-Day Free Trial - - - - -

K Pharma  (TSE:4896) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.


K Pharma Long-Term Debt Related Terms

Thank you for viewing the detailed overview of K Pharma's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


K Pharma (TSE:4896) Business Description

Traded in Other Exchanges
N/A
Address
7-7-7 Roppongi, Minato-ku, Tokyo, JPN, 106-0032
K Pharma Inc is a company involved in Research, development, manufacturing, sales and marketing of pharmaceutical products and regenerative medicine products. It is involved in studying of iPs cells in regnerative medecine to treat neurological conditions such as cerebral infarction and SCI.

K Pharma (TSE:4896) Headlines

No Headlines